MINI REVIEW article
Front. Med.
Sec. Gene and Cell Therapy
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1582975
This article is part of the Research TopicOvercoming Side Effects in Patients Undergoing Immunotherapies and Cell Therapies: A Deeper Evaluation of Advanced Therapeutic Medicinal ProductsView all 3 articles
Toxicities associated with lymphoma-targeting bispecific antibodies -A review
Provisionally accepted
Christopher Doig*
Costas Yannakou- Epworth HealthCare, Melbourne, Australia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Bispecific antibodies (bsAbs) are an emerging class of directed immunotherapies with established uses in certain haematological malignancies as well as an emerging role in the treatment of solid organ malignancy. These molecules are able to juxtapose T cells (in most cases) with target tumour cells, forming an immunological synapse. bsAbs are under extensive investigation in the treatment of B-cell non-Hodgkin lymphomas, with encouraging results in both the monotherapy and combination therapy settings. In this review we summarise the key toxicities associated with the use of lymphoma-targeting bsAbs: cytokine release syndrome, immune eGector cell associated neurotoxicity syndrome, cytopenias, infections and immunosuppression as well as tumour lysis syndrome. While the toxicities are not insignificant, they are typically manageable and justifiable given the unmet medical need, especially in the case of relapsed or refractory disease.
Keywords: BSAB, bispecific antibody, CRS - cytokine release syndrome, ICANS - immune effector cell-associated neurotoxicity syndrome, CD20, Lymphoma
Received: 25 Feb 2025; Accepted: 02 Jun 2025.
Copyright: © 2025 Doig and Yannakou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Christopher Doig, Epworth HealthCare, Melbourne, Australia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.